Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center
Switching from ustekinumab to risankizumab in active CD led to significant clinical and biochemical improvements and high remission rates, particularly in patients with SLOR. These findings support risankizumab as an effective option following ustekinumab failure in refractory CD.
Authors
- Michael Colwill
- Fiona Donovan
- Patrick Dawson (ORCID: https://orcid.org/0000-0002-3175-1275)
- Sailish Honap (ORCID: https://orcid.org/0000-0001-6657-2763)
- James Padley (ORCID: https://orcid.org/0000-0003-0386-7462)
- Andrew P. Poullis (ORCID: https://orcid.org/0000-0003-0703-0328)
- Umang Qazi (ORCID: https://orcid.org/0000-0002-5823-1640)
- Sonia Mehta (ORCID: https://orcid.org/0000-0003-0090-1223)
- Kamal Patel (ORCID: https://orcid.org/0000-0002-8114-2283)
- Ana Margarida Alves (ORCID: https://orcid.org/0000-0003-4739-1419)
- Richard Pollok (ORCID: https://orcid.org/0000-0003-4278-3720)
Institutions
- St George's, University of London (GB)
- King's College London (GB)
- St George’s University Hospitals NHS Foundation Trust (GB)
- King's College School (GB)
Publication Details
- Journal
- World Journal of Gastrointestinal Pharmacology and Therapeutics
- Published
- 2025-12-05
- DOI
- https://doi.org/10.4292/wjgpt.v16.i4.110273
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82